Late Stage Chronic Kidney Disease Therapeutics Market

Late Stage Chronic Kidney Disease Therapeutics Market : Global Industry Analysis 2013 - 2017 and Opportunity Assessment; 2018 - 2028

  • Ongoing
  • May 2020
  • REP-GB-9195
  • PDF PPT EXCEL
Late Stage Chronic Kidney Disease Therapeutics Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Late Stage Chronic Kidney Disease Therapeutics market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Late Stage Chronic Kidney Disease Therapeutics market.


Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.

The dramatic increase in CKD prevalence have maintaining the unmet need for the late stage chronic kidney disease therapeutics. In spite of the introduction of new late stage chronic kidney disease therapeutics the market is expected to have opportunity to grow.

Late Stage Chronic Kidney Disease Therapeutics Market: Drivers and Restraints

The rise in the prevalence of CKD are the main reason for the increasing demand of late stage chronic kidney disease therapeutics. As per to CDC, 15% of the US adults are suffering from CKD and 48% of the CKD patients are not aware of the condition or not on dialysis.

On the other hand the introduction of new late stage chronic kidney disease therapeutics such as calcimimetic and new HK agents is expected to drive the growth of the late stage chronic kidney disease therapeutics market in the forecast period.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus imapact analysis across industries and markets

Request Covid -19 Impact

Favourable reimbursement policy for the late stage chronic kidney disease therapeutics and rising awareness among patients and practitioner for the consequences of CKD is also fuelling the market of late stage chronic kidney disease therapeutics.

In the saturated market of late stage chronic kidney disease therapeutics, the new entrants will face problem to establish their presence in the late stage chronic kidney disease therapeutics market. Although agreements and partnerships between dialysis centers and manufacturers will remain a key strategy to maintain dominance in late stage chronic kidney disease therapeutics market.

Late Stage Chronic Kidney Disease Therapeutics Market: Overview

Global late stage chronic kidney disease therapeutics market has witnessed growth due to rising prevalence of chronic kidney diseases. The introduction of new therapies and favorable reimbursement scenario for the late stage chronic kidney disease therapeutics also propel the growth of the market

Late Stage Chronic Kidney Disease Therapeutics Market: Region-wise Outlook

Geography wise, late stage chronic kidney disease therapeutics market is divided into seven regions viz. North America, Latin America, Europe, Middle East & Africa (MEA), South Asia, East Asia and Oceania. Favorable reimbursement and rising prevalence of CKD in the North American region is expected influence the market and therefore the North America late stage chronic kidney disease therapeutics market will remain dominant in the forecast period.

Late Stage Chronic Kidney Disease Therapeutics Market: Key Market Participants

Some of the market participants in the global late stage chronic kidney disease therapeutics market identified across the value chain include: AbbVie, Amgen, Ardelyx, AstraZeneca, Deltanoid, Genzyme, Keryx, Kyowa Hakko Kirin, Mitsubishi Tanabe, OPKO Health, Relypsa, Sanofi, Shield Therapeutics, Shire, Spectrum, Vifor and ZS Pharma

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Europe (Germany, Italy, France, U.K., Spain, BENELUX, Russia, Rest of Europe)
  • South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia
  • East Asia (China, Japan, South Korea)
  • Oceania (Australia and New Zealand)
  • Middle East and Africa (GCC Countries, S. Africa, Northern Africa, Turkey and Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Late Stage Chronic Kidney Disease Therapeutics Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Late Stage Chronic Kidney Disease Therapeutics Market: Segmentation

To gain a comprehensive and a better understanding of the future late stage chronic kidney disease therapeutics market equity, the market report is segmented based on product type, clinical practice, indication end user and region.

Based on the product type late stage chronic kidney disease therapeutics is segmented into:

  • Calcimimetics
  • Sensipar (cinacalcet hydrochloride)
  • Vitamin D Sterols
  • Nutritional/Native Vitamin D
  • Vitamin D Receptor Agonists
  • Phosphate Binders
  • Calcium-Based Phosphate Binders
  • Aluminum-Containing Phosphate Binders
  • Magnesium-Containing Phosphate Binders
  • Renvela/Renagel
  • Fosrenol (lanthanum carbonate)
  • Velphoro (sucroferric oxyhydroxide)
  • Auryxia (ferric citrate)
  • Potassium Binders
  • Resins
  • Veltassa (patiromer sorbitex calcium)

On the basis of indication, Late Stage Chronic Kidney Disease Therapeutics Market can be segmented as:

  • Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
  • Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
  • Late Stage Chronic Kidney Disease Induced Hyperkalemia

On the basis of end users, late stage chronic kidney disease therapeutics market can be segmented as:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail Order Pharmacy

On the basis of geography, late stage chronic kidney disease therapeutics market can be segmented as:

  • North America
  • Latin America
  • Europe
  • Middle East & Africa (MEA)
  • South Asia
  • East Asia
  • Oceania

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Late Stage Chronic Kidney Disease Therapeutics Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Late Stage Chronic Kidney Disease Therapeutics Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology